FeesSafety
Pluang+

Everpure's $7B revenue forecast beats Wall Street, shares jump 11%, driven by hyperscaler deals.

Market News
27 Sep 2026, 18:45 WIB
24/7 Wall Street
View Source
Bullish
Everpure's $7B revenue forecast beats Wall Street, shares jump 11%, driven by hyperscaler deals.

Everpure announced a fiscal 2028 revenue forecast of $7 billion to $7.3 billion, significantly surpassing Wall Street's consensus of $6.14 billion. This strong outlook, driven by new design wins and supply agreements with major hyperscalers, boosted shares by over 11%. However, risks remain from low product margins, negative cash flow due to strategic NAND purchases, and customer concentration. The key to sustaining growth lies in the timely ramp-up of hyperscaler demand and margin improvements, with the next fiscal quarter report as a critical checkpoint.

Everpure's fiscal 2028 revenue forecast is the subject, with Pluang market data providing context as of Sep 27, 2026 21:51 WIB. For readers following Technology-sector US stocks on Pluang, 66 of 150 stocks rose and 82 fell today. Notable movers include TWLO at USD 275.80 with a -7.96% change and 100% buy order activity, CRDO at USD 210.97 up 7.65% with 94% sell orders, and AEHR at USD 104.39 up 7.15% with 97% buy orders. The most notable figure is TWLO's 100% buy order activity.

More News

Global music market to grow at 8.07% CAGR, reaching $57.74B by 2032 driven by streaming and digital access.

Global music market to grow at 8.07% CAGR, reaching $57.74B by 2032 driven by streaming and digital access.

The global music market is projected to grow from $36.13 billion in 2026 to $57.74 billion by 2032, at a CAGR of 8.07%, fueled by paid streaming subscriptions, smartphone adoption, and digital music discovery. North America remains the largest market...

Market News
Bullish
15 minutes ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
2 hours ago
China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
2 hours ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
2 hours ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App